217 related articles for article (PubMed ID: 26318737)
21. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
22. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
[TBL] [Abstract][Full Text] [Related]
23. Plk1 activation by Ste20-like kinase (Slk) phosphorylation and polo-box phosphopeptide binding assayed with the substrate translationally controlled tumor protein (TCTP).
Johnson TM; Antrobus R; Johnson LN
Biochemistry; 2008 Mar; 47(12):3688-96. PubMed ID: 18298087
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
[TBL] [Abstract][Full Text] [Related]
25. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.
Ramani P; Headford A; May MT
Virchows Arch; 2013 Feb; 462(2):203-9. PubMed ID: 23307190
[TBL] [Abstract][Full Text] [Related]
26. The influence of biologic factors on the surgical decision in advanced neuroblastoma.
Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ
Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884
[TBL] [Abstract][Full Text] [Related]
27. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
28. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
29. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
Singh L; Pushker N; Sen S; Singh MK; Chauhan FA; Kashyap S
Clin Exp Ophthalmol; 2015 Aug; 43(6):550-7. PubMed ID: 25754767
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
Cucchi U; Gianellini LM; De Ponti A; Sola F; Alzani R; Patton V; Pezzoni A; Troiani S; Saccardo MB; Rizzi S; Giorgini ML; Cappella P; Beria I; Valsasina B
Anticancer Res; 2010 Dec; 30(12):4973-85. PubMed ID: 21187478
[TBL] [Abstract][Full Text] [Related]
32. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
33. The Relationship Between Apoptotic Activity and Prognostic Factors in Neuroblastomas.
Ekmekci S; Olgun N; Özer E
Turk Patoloji Derg; 2016; 32(2):99-104. PubMed ID: 27136108
[TBL] [Abstract][Full Text] [Related]
34. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
36. Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment.
Liu L; Zhang M; Zou P
Oncology; 2008; 74(1-2):96-103. PubMed ID: 18547964
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
38. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Dungwa JV; Hunt LP; Ramani P
Hum Pathol; 2012 Oct; 43(10):1651-60. PubMed ID: 22436629
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
[TBL] [Abstract][Full Text] [Related]
40. PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
Fernández-Aceñero MJ; Cortés D; Gómez del Pulgar T; Cebrián A; Estrada L; Martínez-Useros J; Celdrán A; García-Foncillas J; Pastor C
Pathol Oncol Res; 2016 Apr; 22(2):377-83. PubMed ID: 26577686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
